TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 05/09/25

2025-05-09 09:26:09 ET Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Results Conference Call May 08, 2025 06:00 AM ET Company Participants Christopher O’Reilly - Head, Investor Relations Christophe Weber - President & Chief Executive Officer Mila...

2025-05-08 02:49:10 ET Read the full article on Seeking Alpha For further details see: Takeda Pharmaceutical Non-GAAP EPS of ¥491.00, revenue of ¥4581.6B; initiates FY25 outlook

2025-04-24 07:46:40 ET Summary Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. It beat the consensus estimates again by a wide margin, thanks to its leading positions in the oncology and immunology market. So, sales of Tremf...

2025-04-23 11:10:00 ET Summary Grifols, a Spanish multinational specializing in plasma-derived therapies, is undervalued due to historical mismanagement but holds a strong market position with significant competitive advantages. New management has implemented an operational improv...

2025-04-23 10:50:00 ET Summary The White Falcon portfolio underperformed due to losses in larger positions, despite gains from gold and silver royalties; Converge Technologies was acquired at a premium. Market volatility increased post-quarter due to President Trump's tariff annou...

2025-04-11 14:13:24 ET Summary Keros Therapeutics, Inc. halted its phase 2 TROPOS trial of cibotercept for treatment of patients with PAH due to safety concerns, but expects topline data in Q2, 2025 from it. Promising phase 1 data for KER-065 in DMD and a strategic review could of...

2025-04-09 15:59:57 ET Summary The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are s...

2025-04-01 14:27:17 ET Summary Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Icotrokinra show strong Phase III results, with poten...

2025-03-13 03:45:02 ET Summary Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they have a robust drug discovery pipeline to meet futur...

2025-03-11 16:00:09 ET Summary Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, s...